Drug Patents owned by Fennec Pharms Inc

1. List of Pedmark drug patents

PEDMARK Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190 FENNEC PHARMS INC Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
Jan, 2038

(14 years from now)

US11617793 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(16 years from now)

US11291728 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(16 years from now)

US11510984 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 20, 2025
Orphan Drug Exclusivity (ODE) Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PEDMARK before it's patent expiration?
More Information on Dosage

PEDMARK family patents

15

United States

3

Australia

3

Brazil

3

Canada

3

Korea, Republic of

3

China

3

Singapore

3

Israel

3

Japan

3

European Union

2

Morocco

1

Russia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in